Avacta wins pre|CISION R&D award, but AVA6103’s H1 2027 efficacy test matters more

Avacta Group plc (AIM: AVCT), a London-headquartered clinical-stage oncology biotechnology company, has advanced its AVA6103 programme to dose level 4 in the FOCUS-01 Phase 1 trial while its pre|CISION drug-delivery platform received the Research and Development Achievement Award at the Pharma Industry Awards UK 2026. The September 25 update follows preliminary human data showing AVA6103 was well tolerated through the first three dose levels, including exposure to an exatecan payload approximately 50% above the maximum tolerated dose of conventional exatecan. Patients are now being treated at a fourth dose level representing more than double that conventional exatecan maximum tolerated payload dose, as Avacta Group plc tests how far tumour-targeted delivery can widen the therapeutic window. The strategic importance is considerably greater than the industry award itself because AVA6103 is becoming the first second-generation pre|CISION medicine to test whether Avacta can repeatedly deliver a highly potent topoisomerase I payload at exposure levels that conventional administration may not tolerate. The unresolved issue is efficacy, with Avacta now pointing to an initial FOCUS-01 efficacy readout in the first half of 2027 rather than relying only on pharmacokinetics and early safety evidence.

What has Avacta Group actually demonstrated with AVA6103 in the FOCUS-01 Phase 1 trial so far?

The most important evidence currently available from FOCUS-01 concerns mechanism, pharmacokinetics and tolerability rather than confirmed clinical efficacy. Avacta reported in September that pharmacokinetic results from the first three dose levels were closely aligned with modelling derived from preclinical work, with evidence that exatecan was being released in patients over a period of days. That correspondence between modelled and observed behaviour matters because the pre|CISION thesis depends on the conjugated medicine remaining comparatively controlled in circulation before the peptide is cleaved within fibroblast activation protein-rich tumour tissue.

AVA6103 combines the pre|CISION peptide architecture with exatecan, a potent topoisomerase I inhibitor. The objective is not merely to deliver another cytotoxic medicine but to alter where and for how long the active payload is released, potentially permitting a level of dose intensity that would be difficult to achieve through conventional systemic delivery. Through the first three cohorts, Avacta said patients tolerated payload exposure reaching approximately 50% above the maximum tolerated dose previously associated with conventional exatecan.

The fourth dose level materially raises the test. Avacta said the absolute payload exposure at this level is more than twice the maximum tolerated dose of conventional exatecan and approaches the equivalent topoisomerase I inhibitor payload exposure associated with the approved dose of Enhertu in breast cancer. That comparison provides useful pharmacological context, but it does not establish that AVA6103 is equivalent or superior to Enhertu because the medicines use different targeting architectures, clinical populations and development programmes.

The available human evidence therefore supports a narrower conclusion. AVA6103 has so far behaved sufficiently close to Avacta’s predicted pharmacokinetic profile to justify continued dose escalation, and the early tolerability data have allowed the company to investigate substantially higher payload exposure. Whether that additional exposure produces a clinically meaningful increase in tumour response without introducing new toxicity is the central question that later FOCUS-01 data must answer.

Why does dose level 4 matter for Avacta’s attempt to expand the therapeutic window of exatecan?

The economic case for pre|CISION ultimately rests on therapeutic window rather than drug delivery as an abstract technological achievement. Potent oncology payloads create value when sufficient drug reaches malignant tissue to produce durable antitumour activity while systemic exposure remains manageable enough for treatment to continue. If targeting allows more payload to be delivered safely, clinicians may gain flexibility around dose, dosing interval and treatment duration.

Avacta is exploring that possibility through both conventional and more dose-dense scheduling within FOCUS-01. The trial includes an every-two-week arm, and patients with pancreatic ductal adenocarcinoma are being enrolled into this dose-intense schedule. The company argues that its peptide-based conjugate can support more frequent administration because the pre|CISION peptide does not have the same accumulation characteristics as an antibody and because the controlled-release mechanism is intended to limit systemic exposure to free payload.

This differentiates AVA6103 conceptually from established antibody drug conjugates even though the commercial benchmark remains influenced by the success of topoisomerase I payload medicines. Enhertu and Datroway have helped validate the broader proposition that highly potent topoisomerase I inhibitors can create significant oncology products when paired with effective targeting and delivery technology. Avacta is attempting to reach a similar pharmacological objective through fibroblast activation protein-mediated tumour activation rather than antibody binding to a specific tumour-associated antigen.

The fourth dose level should therefore be viewed as a stress test of that architecture. Remaining well tolerated at a payload exposure more than twice the conventional exatecan maximum tolerated dose would add to evidence that pre|CISION can alter systemic tolerability. The commercial relevance, however, will depend on showing that the additional payload translates into stronger tumour control rather than simply demonstrating that more drug can be administered.

Why is pancreatic ductal adenocarcinoma becoming an important test case for AVA6103 and pre|CISION?

Avacta used the American Association for Cancer Research Conference on Pancreatic Cancer in San Diego to present the FOCUS-01 design and additional preclinical evidence supporting AVA6103 in pancreatic ductal adenocarcinoma. In patient-derived xenograft models of pancreatic cancer, the company reported tumour-targeted exatecan delivery and durable complete and partial responses that persisted for weeks after dosing stopped. These remain animal data and cannot establish the clinical response that patients will experience, but they provide the biological rationale for including pancreatic cancer prominently in the clinical programme.

The company also reported high fibroblast activation protein expression in pancreatic ductal adenocarcinoma samples, with fibroblast activation protein-expressing cancer-associated fibroblasts positioned close to blood vessels and tumour cells. That spatial relationship is relevant to Avacta’s proposed mechanism because the conjugate must enter the tumour microenvironment, encounter sufficient fibroblast activation protein activity and release exatecan where the payload can reach malignant cells.

FOCUS-01 is broader than pancreatic cancer. The dose-escalation study was designed to include six selected advanced solid-tumour groups, with tumour selection informed partly by Avacta’s collaboration with Tempus AI and analysis of fibroblast activation protein expression alongside biological markers associated with sensitivity to topoisomerase I inhibition. This approach attempts to increase the probability that early clinical testing occurs in cancers where both the targeting mechanism and the payload have a plausible biological fit.

Pancreatic cancer nevertheless offers a particularly demanding setting for the platform. Strong preclinical activity would carry considerably greater weight if it is followed by reproducible responses in patients, especially if dose intensity can be maintained without the toxicity that often constrains potent chemotherapy. Conversely, favourable pharmacokinetics without corresponding tumour responses would show that successful drug delivery is only one component of clinical effectiveness.

How much should investors read into the pre|CISION Research and Development Achievement Award?

The Pharma Industry Awards UK recognition gives Avacta external industry acknowledgement at a useful point in the development cycle. The award cited progress made with pre|CISION during the preceding year, including the movement of the next-generation platform into clinical development through AVA6103. For a smaller biotechnology company seeking pharmaceutical partnerships, recruiting clinical investigators and building awareness of a proprietary delivery platform, that type of recognition can support visibility.

It should not be confused with regulatory validation or clinical proof of efficacy. An industry award does not alter the endpoints of FOCUS-01, establish an acceptable benefit-risk profile or reduce the evidence required for future regulatory approval. The value of the award is consequently reputational rather than a direct change in the probability of commercialisation.

Its timing is still noteworthy because Avacta is attempting to demonstrate that pre|CISION is a repeatable drug-development platform rather than technology tied predominantly to AVA6000. AVA6000 established first-generation human evidence using doxorubicin, while AVA6103 introduces a substantially more potent payload and a sustained-release architecture. If AVA6103 can produce convincing human efficacy while maintaining the emerging tolerability profile, the platform could become more relevant to potential partners interested in applying pre|CISION chemistry to other oncology payloads.

That commercial pathway remains conditional. Avacta has previously disclosed discussions with multiple potential partners across different generations of the platform, but no partnership should be valued as completed economics until an agreement is signed and its financial terms are known. The next clinical dataset could therefore have more influence on partnership leverage than the award itself.

What does the latest AVCT share-price performance say about market confidence in AVA6103?

Avacta Group plc shares closed at 72.8 pence on September 25, down 1.6% during the session in which the latest FOCUS-01 update and the pre|CISION award were announced. The stock had closed at 78.6 pence on September 16, when Avacta announced the preliminary AVA6103 proof-of-mechanism data, leaving the September 25 close approximately 7.4% below that level. The movement does not establish that investors reacted negatively to the scientific update because biotechnology share prices can respond to multiple factors, but it indicates that the early mechanistic evidence has not produced a sustained rerating.

The wider timeframe is more balanced. AVCT closed at 69.2 pence on August 26, meaning the September 25 price was roughly 5% higher over one month. The shares also remained modestly above the 70 pence price used for Avacta’s £9 million June equity financing while sitting below their 52-week high of 92 pence and well above the 48 pence low.

Using approximately 468.4 million shares outstanding, the September 25 close implies an equity value of around £341 million. That valuation already incorporates expectations around AVA6000, AVA6103, the wider pre|CISION platform and potential future partnerships, even though Avacta remains a clinical-stage company without commercial oncology product revenue. The stock can therefore react sharply not only to whether clinical data are positive, but also to whether new evidence is strong enough to alter the probability assigned to eventual development success.

The September trading pattern also illustrates the distinction between mechanistic validation and efficacy validation. AVA6103 has provided evidence supporting the intended release behaviour, but investors do not yet have mature response data with which to estimate clinical competitiveness, addressable indications or future licensing economics. A credible efficacy signal in H1 2027 would provide a substantially different valuation input from the pharmacokinetic evidence available today.

How does Avacta’s remaining funding and convertible bond position affect the AVA6103 timetable?

Clinical progress continues alongside a capital structure that requires attention. Avacta reported cash and short-term deposits of £16.9 million at the end of 2025 and £16.4 million at April 30, 2026. During 2026 it completed equity financings intended both to extend its operating runway and to reduce exposure to its convertible bond, including the £9 million June financing issued at 70 pence per share.

On September 4, Avacta disclosed a further £2.613 million cash settlement covering one deferred quarterly convertible bond repayment. Following that payment and the July scheduled payment, the company said £12 million of principal remained outstanding under the convertible bond. Those repayments reduce the remaining debt balance but consume cash, which makes the timing of clinical milestones, future development spending and any partnership income financially relevant.

Avacta had previously described its funding as extending into early Q1 2027 and beyond the initial AVA6103 clinical data. The latest September presentation now places the initial efficacy readout in H1 2027, creating a narrower relationship between the company’s previously communicated runway and the next major efficacy catalyst. The company has not provided enough new information in the September 25 announcement to conclude that the earlier runway guidance has changed, so the appropriate focus is on future cash updates rather than extrapolating an unsupported new runway date.

A partnership could materially alter that equation if it brings upfront or research funding, while another equity financing could extend development capacity at the cost of additional dilution. Stronger AVA6103 data could improve Avacta’s negotiating position in either scenario. Weak or ambiguous efficacy data would make capital allocation more difficult because the company would still need to decide how aggressively to fund AVA6103 alongside AVA6000 and its broader platform.

What evidence will determine whether AVA6103 becomes genuine platform validation for Avacta Group?

The September developments have moved AVA6103 beyond the stage where preclinical promise alone defines the programme. The first three FOCUS-01 cohorts have produced preliminary evidence consistent with the intended pharmacokinetic mechanism, while progression to dose level 4 is testing whether substantial payload escalation remains tolerable. That is meaningful technical progress because a drug-delivery platform must first demonstrate that it can control exposure before efficacy can be interpreted in the context of dose.

The next step is harder. Avacta needs response data showing that tumour-targeted release translates into clinically relevant antitumour activity across enough patients to distinguish a repeatable signal from individual cases. Duration of response, dose-response relationships, safety at higher exposure, performance of the every-two-week schedule and differences between tumour types will all become more important as the dataset matures.

If those measures begin to align, AVA6103 would provide evidence that pre|CISION can support a second payload class and a second generation of chemistry in humans, strengthening the argument that Avacta owns a broader oncology delivery platform rather than a small collection of unrelated experimental medicines. If pharmacokinetic success is not followed by efficacy, the value of the technology would need to be reassessed around which payloads, tumours and dosing strategies are most suitable.

The Research and Development Achievement Award recognises how far the platform has advanced. The more consequential test now comes from FOCUS-01, where dose level 4 and the H1 2027 efficacy readout should begin determining whether increased exatecan exposure can produce the clinical benefit required to convert scientific validation into commercial leverage.

Key takeaways on Avacta Group, AVA6103, pre|CISION and the H1 2027 efficacy readout

• Avacta Group plc has progressed AVA6103 into dose level 4 of the FOCUS-01 Phase 1 trial after preliminary safety and pharmacokinetic data supported continued escalation.
• The first three dose levels included payload exposure approximately 50% above the maximum tolerated dose of conventional exatecan.
• Dose level 4 represents more than twice the conventional exatecan maximum tolerated payload dose and approaches the equivalent topoisomerase I payload exposure of approved-dose Enhertu.
• Early human evidence supports the intended controlled-release mechanism, but it does not yet establish meaningful clinical efficacy.
• Avacta now expects an initial FOCUS-01 efficacy readout during H1 2027, making tumour-response data the next major test of the second-generation platform.
• Updated pancreatic cancer preclinical studies showed durable responses in patient-derived xenograft models, but those findings still require confirmation in patients.
• The pre|CISION Research and Development Achievement Award provides industry recognition without changing the regulatory or clinical evidence required for AVA6103.
• AVCT shares closed at 72.8 pence on September 25, about 7.4% below their September 16 close but roughly 5% above their August 26 level.
• Approximately £12 million of convertible bond principal remained after Avacta’s September cash repayment, keeping clinical progress and funding requirements closely connected.
• Strong H1 2027 efficacy data could strengthen the case for pre|CISION as a repeatable oncology platform and increase Avacta’s leverage in potential partnership discussions.